Pharmao

Pharmao was a French biotechnology company focused on the development of novel small molecule therapeutics targeting the endocannabinoid system. The company specialized in the discovery of selective Cannabinoid receptor 2 (CB2) agonists, which were designed to treat chronic and neuropathic pain while avoiding the central nervous system side effects typically associated with CB1 receptor activation. Their lead candidate, O-1963, was developed as a potent analgesic for conditions where current treatments like opioids were inadequate or poorly tolerated. Pharmao's research was rooted in advanced cannabinoid pharmacology and aimed to provide safer, non-addictive alternatives for pain management before the company ceased operations.